Valneva's wild stock-price rise continued on Monday after the French biotech said its coronavirus vaccine candidate outperformed AstraZeneca's in a trial.

from MarketWatch.com - Top Stories https://ift.tt/3FYVGdJ
via IFTTT
from MarketWatch.com - Top Stories https://ift.tt/3FYVGdJ
via IFTTT
Kommentare
Kommentar veröffentlichen